Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors - Full Text View

Sponsors and Collaborators:	UPMC Cancer Centers National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00009802

Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may increase the effectiveness of paclitaxel by making tumor cells more sensitive to the drug.

PURPOSE: Phase I trial to study the effectiveness of combining calcitriol with paclitaxel in treating patients who have advanced solid tumors.

Condition	Intervention	Phase
Unspecified Adult Solid Tumor, Protocol Specific	Dietary Supplement: calcitriol Drug: paclitaxel	Phase I

MedlinePlus related topics: Cancer

Drug Information available for: Calcitriol Paclitaxel

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	A Phase I Trial Of Oral Calcitriol [1,25-(OH)2D3] And Paclitaxel In Advanced Solid Tumors

Further study details as provided by National Cancer Institute (NCI):

Study Start Date:

June 1998

Detailed Description:

OBJECTIVES:

Determine the toxic effects and maximum tolerated dose of calcitriol when combined with paclitaxel in patients with advanced solid tumors.
Determine the effect of administration of calcitriol on the pharmacokinetics of paclitaxel in these patients.
Determine the effect of administration of paclitaxel on the pharmacokinetics of calcitriol in these patients.

OUTLINE: This is a dose-escalation study of calcitriol.

During course 1, patients receive oral calcitriol daily on days 1-3 of weeks 1-6 and paclitaxel IV over 1 hour on day 1 of week 1 and day 3 of weeks 2-6.

During course 2 and subsequent courses, patients receive oral calcitriol daily on days 1-3 and paclitaxel IV over 1 hour on day 3 of weeks 1-6. Treatment continues every 8 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of calcitriol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the highest dose giving an estimated probability of dose-limiting toxicity of no more than 0.30.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically proven advanced cancer not curable by standard therapies
Brain metastases allowed following definitive radiotherapy

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

ECOG 0-2

Life expectancy:

Not specified

Hematopoietic:

Absolute neutrophil count at least 1,500/mm^3
Platelet count at least 100,000/mm^3

Hepatic:

Bilirubin no greater than 1.5 mg/dL
SGOT no greater than 4 times normal

Renal:

Creatinine no greater than 2.0 mg/dL
Calcium no greater than 10.5 mg/dL

Other:

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective double-barrier contraception for at least 1 week before, during, and for at least 2 weeks after study
No active infection or serious concurrent condition
No symptomatic peripheral neuropathy greater than grade 1

PRIOR CONCURRENT THERAPY:

Biologic therapy:

At least 3 weeks since prior regional or systemic biologic therapy

Chemotherapy:

At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea)

Endocrine therapy:

Not specified

Radiotherapy:

See Disease Characteristics
At least 3 weeks since prior radiotherapy

Surgery:

Not specified

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00009802

Locations

United States, Pennsylvania
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States, 15213-3489

Sponsors and Collaborators

UPMC Cancer Centers

National Cancer Institute (NCI)

Investigators

Study Chair:

Ramesh K. Ramanathan, MD

UPMC Cancer Centers

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	CDR0000068411, PCI-98019, PCI-IRB-980542, NCI-G00-1901
Study First Received:	February 2, 2001
Last Updated:	February 6, 2009
ClinicalTrials.gov Identifier:	NCT00009802 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

unspecified adult solid tumor, protocol specific

Study placed in the following topic categories:

Calcium, Dietary
Paclitaxel
Vitamins
Tubulin Modulators
Vasoconstrictor Agents
Bone Density Conservation Agents

Trace Elements
Antimitotic Agents
Cardiovascular Agents
Micronutrients
Antineoplastic Agents, Phytogenic
Calcitriol

Additional relevant MeSH terms:

Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Growth Substances
Mitosis Modulators
Physiological Effects of Drugs
Calcium Channel Agonists
Bone Density Conservation Agents
Antimitotic Agents
Cardiovascular Agents
Pharmacologic Actions

Calcitriol
Membrane Transport Modulators
Paclitaxel
Therapeutic Uses
Vitamins
Tubulin Modulators
Vasoconstrictor Agents
Micronutrients
Antineoplastic Agents, Phytogenic

ClinicalTrials.gov processed this record on May 06, 2009